TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Loop Duodenal Switch Surgery in Morbidly Obese Patients

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: CASE_ONLY
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~1. The subject must be 18-70 years of age at time of enrollment.~2. The subject must be willing and able to participate in the study procedures and to understand and sign the informed consent.~3. The subject is under consideration for surgery for obesity or metabolic disease and elects to undergo a primary loop duodenal switch procedure or as a conversion procedure for failed, sustained weight loss after a sleeve gastrectomy or laparoscopic adjustable gastric band performed more than 12 months prior to time of evaluation.~4. The subject has a BMI of greater than or equal to 40 kg/m2 at time of surgical consultation.~Exclusion Criteria:~1. Subjects under 18 years of age or older than 70 years of age.~2. Subject is not willing or able to participate in the study procedures and understand the informed consent.~3. The subject wishes to under a different bariatric procedure other than the loop duodenal switch.~4. The subject has a BMI of less than 40 kg/m2 at the time of surgical consultation.~5. Any female subject who is pregnant, or is actively breast-feeding~6. Any subject who is considered to be part of a vulnerable population (eg. prisoners or those with psychological concerns or those without sufficient mental capacity)~7. The procedure is an emergency procedure~8. The subject is unable to unwilling to comply with the study requirements or follow-up schedule.~9. The subject has comorbidities which, in the opinion of the investigator, will not be appropriate for the study (eg. severe cardiovascular disease or history of gastrointestinal malignancy, history of upper GI gastric surgery, history of intestinal surgery, open cholecystectomy, immunosuppression, and non-ambulatory).~10. The subject has an estimated life expectancy of less than 6 months.~11. The subject has participated in an investigational drug or device research study within 30 days of enrollment.~12. The subject's insurance company does not cover a duodenal switch operation as treatment for morbid obesity.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Effect of a Perioperative Oral Nutritional Supplementation on Patients Undergoing Hepatic Surgery for Liver Cancer

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2/PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Adult over 18 years~* Hepatectomy of at least 2 segments~* For primary or secondary cancer~* With cirrhosis (Child Pugh \<8) or liver fibrosis (fibrosis score of 3)~* Informed written consent~Exclusion Criteria:~* Pregnancy~* Recent weight loss of more than 10% of body weight~* Immunological deficiency~* Portal or hepatic arterial thrombosis~* Biliary duct dilation

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- 1 (Type: EXPERIMENTAL): Perioperative Oral Nutritional Supplementation
- 2 (Type: PLACEBO_COMPARATOR): Placebo of Perioperative Oral Nutritional Supplementation

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Microsurgical Varicocelectomy Versus No Surgery in Men With a Palpable Varicocele and an Abnormal Semen Analysis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* 6 months of infertility (primary or secondary - randomization will be stratified to allow equal numbers of primary and secondary infertility couples in the treatment vs. observation group), male partner \> 18 years of age and \< 50 years of age~* Female partner \> 18 years of age and \<= 40 years of age - randomization will be stratified for two groups - female partner \<35 and female partner \>=35~* Evidence of a hysterosalpingogram or Saline Infusion Sonogram with one patent tube and regular ovulatory cycles as defined by the recruiting site \>25 days and \<35 days in duration in the female partner~* Evidence of a bilateral grade I or unilateral grade II-III varicocele on physical exam in the male partner~* Abnormal semen analysis as defined by WHO II criteria with a sperm count of \>5 X106 /ml or the presence of abnormal strict morphology as defined by Kruger criteria.~Exclusion Criteria:~* The presence of retrograde ejaculation or uncorrectable ejaculatory dysfunction~* Decreased ovarian reserve in the female partner as evidence by a day #3 FSH \> 12 mIU/ml

- Gender: MALE
- Minimum Age: 18 Years
- Maximum Age: 50 Years
- Healthy Volunteers: f

Study Arms:
- No surgery + IUI (Type: ACTIVE_COMPARATOR): No microsurgical varicocelectomy plus up to four cycles each of alternating intrauterine insemination and timed intercourse starting with intrauterine insemination.
- No Surgery + TI (Type: ACTIVE_COMPARATOR): No microsurgical varicocelectomy plus up to four cycles each of alternating intrauterine insemination and timed intercourse starting with timed intercourse.
- Surgery + IUI (Type: ACTIVE_COMPARATOR): Microsurgical varicocelectomy plus up to four cycles each of alternating intrauterine insemination and timed intercourse starting with intrauterine insemination.
- Surgery + TI (Type: ACTIVE_COMPARATOR): Microsurgical varicocelectomy plus up to four cycles each of alternating intrauterine insemination and timed intercourse starting with timed intercourse.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Standard Pain Control or Intrathecal Therapy in Controlling Pain in Patients With Locally Advanced, Unresectable, or Metastatic Pancreatic Cancer

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: SUPPORTIVE_CARE
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
DISEASE CHARACTERISTICS:~Inclusion criteria:~* Histologically confirmed adenocarcinoma of the pancreas~  * Mixed adenocarcinoma tumors allowed provided the predominant invasive component of the tumor is adenocarcinoma~* Locally advanced, unresectable, or metastatic disease~* Patients must be within two months of diagnosis or have started chemotherapy within 60 days of study~* Average pain score ≥ 4/10 over a 7-day period on a verbal numerical rating scale~Exclusion criteria:~* Known brain metastases~* Tumor with clinically significant obstruction of the spinal canal~PATIENT CHARACTERISTICS:~Inclusion criteria:~* Karnofsky performance status 60-100%~* ANC ≥ 1,500 cells/mm³~* Hematocrit ≥ 28%~* WBC ≥ 3,500 cells/mm³~* Platelets ≥ 90,000/mm³~* Serum creatinine ≤ 2.0 mg/dL~* Bilirubin ≤ 2.5 mg/dL~* AST/ALT ≤ 5 times upper limit of normal (ULN)~* Alkaline phosphatase ≤ 5 times ULN~* INR ≤ 1.5~* Not pregnant or nursing~* Negative pregnancy test~* Mini-mental status exam score ≥ 22~Exclusion criteria:~* Uncontrolled medical conditions that could potentially increase the risk of toxicities or complications of this therapy, including any of the following:~  * Gastrointestinal tract disease resulting in an inability to take oral medication or a requirement for IV alimentation~ * Active peptic ulcer disease~* Active infections~* Insensitive to opioid medication for cancer pain~* Insufficient tissue or decubitus ulcer near device implantation site~* Current history of substance abuse~PRIOR CONCURRENT THERAPY:~* Minor procedures (i.e., dental work or skin biopsy), tumor biopsies, and biliary stent placement are allowed~* No prior surgical procedures affecting absorption~* Prior or other concurrent pain medications are allowed~* Concurrent chemotherapy or radiotherapy allowed at the discretion of the treating physician

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- morphine (Type: ACTIVE_COMPARATOR): morphine given traditionally (IV, pill, patch). This is standard of care dosing.
- Intrathecal pump (Type: ACTIVE_COMPARATOR): Pump internal used to deliver morphine. This is a newer method for delivery of morphine. Morphine is FDA approved for intrathecal use. The intrathecal pump will be titrated gradually to effect by the interventional pain medicine team. These are the maximum doses and concentrations in keeping with the Polyanalgesic Consensus Conference guidelines: Dose (mg/day):15 ; Conc (mg/cc): 20

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Non-Myeloablative Allogeneic HSCT From HLA Matched Related or Unrelated Donors for the Treatment of Low Grade B Cell Malignancies

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2/PHASE3
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Stage II or III non-progressive disease Multiple Myeloma.~* CLL/SLL, and low grade Hodgkin Lymphomas that are in a very good partial response or complete response with non-progressive disease.~* ≤ 70 years old.~* Eligible and willing HLA matched related donor.~* Bilirubin \<2xULN.~* ALT and AST \<3xULN.~* LVEF \> 40%.~* Creatinine Clearance \>40mL/min.~* Pulmonary function DLCO corrected to ≥ 70%.~* Minimum performance score of 70%.~* Platelet count \>130 x103 micro L.~* LDH ≤1.5xULN.~* No proceeding co-morbid condition that significantly increases the risk of severe regimen related toxicity.~* No uncontrolled infections.~Exclusion Criteria:~* Age \>70 years old.~* Performance status \<70%.~* Uncontrolled infections or is HIV positive~* Prior malignancies that are felt to have a \<80% probability of being cured.~* Pregnant, breastfeeding, or refuse to use contraceptive techniques during and for 12 months following transplant.~* Prior Allograft~* History of rapidly growing disease at diagnosis or at any progression or have MDS.~* No eligible and willing HLA matched donor.

- Gender: ALL
- Minimum Age: 19 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Study Arms:
- Non Myeloablative Treatment (Type: OTHER): Non-myeloablative Transplant Conditioning Chemotherapy :~Fludarabine - 30 mg/m2/day x 3 days Total Body Irradiation - 200cGy x1 dose Infusion of Stem Cells - On Day 0 pts will received an infusion of HLA matched sibling donor stem cells. Dose is determined by the volume of cells obtained from donor. Minimum dose is 2x10\*6 CD34+ cells per kilogram of recipient weight.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Optical Coherence Tomography (OCT) Reference Data Collection Study (S-2015-1)

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: DIAGNOSTIC
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Able and willing to undergo the test procedures, give consent, and to follow instructions.~* Signed informed consent~* Age ≥18 to 90.~* Healthy eye without prior intraocular surgery (except cataract surgery and Laser in Situ Keratomileusis) and without clinically significant vitreal, retinal or choroidal diseases, clinically significant diabetic retinopathy (subject may have diabetes), or disease of the optic nerve. Small drusen are acceptable in older subjects.~* Black or African-American decent (self-reported)~* Negative history of glaucoma (not including family history)~* Intraocular pressure ≤21mmHg.~* Best corrected visual acuity ≥20/40.~* Refraction between +6 and -6 diopters and astigmatism ≤ 2 diopters.~* Axial length ≤ 26.0 mm (by optical biometry)~* Normal visual field with Glaucoma Hemifield Test and Mean Deviation within normal limits or not abnormal visual field by judgment of the ophthalmologist / optometrist~* Clinically normal appearance of the optic disc, with normal appearing neuroretinal rim with respect to color and shape. The optic disc is examined ophthalmoscopically and by evaluation of stereo photographs.~* If both eyes are eligible, both eyes enter the study.~Exclusion Criteria:~* Vulnerable subjects (as defined in ISO 14155 GCP) with the exception of employees of the site, and, if applicable, students of the respective university. Staff that is listed on the delegation form are excluded from participation.~* Subjects unable to read or write~* Unreliable visual field. The reliability indices should be used as guide as well as the perimetrist's notes.~* Unusable disc stereo photos.~* Inability to undergo the tests.~* Insufficient quality of Spectralis OCT images (this is not determined until after Spectralis OCT examination, and is an unusual circumstance).~Minimum requirements are:~* Retina completely included in image frame,~* Quality Score ≥ 20 in the stored ART mean images, and~* For ONH-R scan: Center position error ≤ 100 μm.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 90 Years
- Healthy Volunteers: t

Study Arms:
- Normal healthy Volunteers (Type: EXPERIMENTAL): OCT imaging

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Licorice Root Extract and Docetaxel in Treating Patients With Metastatic Prostate Cancer That Did Not Respond to Hormone Therapy

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
DISEASE CHARACTERISTICS:~* Diagnosis of prostate adenocarcinoma~  * Metastatic disease~* Must have failed initial hormonal therapy and have disease progression after at least one chemotherapy regimen\*, meeting any of the following criteria:~  * Progressive PSA ≥ 5 ng/mL, as evidenced by 2 separate measurements taken ≥ 2 weeks apart with the second PSA measurement greater than the first one and PSA measurement at screening greater than the first one~ * Progressive measurable disease (e.g., changes in the size of lymph nodes or parenchymal masses or appearance of new lesions on physical examination or x-ray/CT scan) with a PSA level at screening ≥ 5 ng/mL~ * Progressive bone metastasis (e.g., presence of new lesions on a bone scan) with a PSA level at screening ≥ 5 ng/mL NOTE: \*Prior chemotherapy must include a taxane therapy, but disease progression does not have to follow taxane therapy~* Patients must maintain primary androgen ablation (hormonal) therapy AND experience disease progression while not receiving antiandrogen therapy~PATIENT CHARACTERISTICS:~* ECOG performance status 0-1~* Life expectancy ≥ 6 months~* Absolute neutrophil count ≥ 1,500/mm\^3~* Platelet count ≥ 100,000/mm\^3~* WBC ≥ 3,500/mm\^3~* Bilirubin ≤ 1.2 mg/dL~* Creatinine ≤ 1.5 mg/dL~* SGOT or SGPT ≤ 1.5 times upper limit of normal~* No other prior malignancy unless treated with curative intent and free of disease for the time period considered appropriate for the specific cancer~* No uncontrolled hypertension~* No active infections~* No known HIV positivity~* No uncontrolled medical condition that would preclude study therapy~* No diagnosis of major depression or suicidal ideation~* No problems with oral absorption~PRIOR CONCURRENT THERAPY:~* See Disease Characteristics~* More than 4 weeks since prior surgery or radiotherapy and recovered~* At least 4 weeks since prior flutamide~* At least 6 weeks since prior bicalutamide~* No prior or concurrent herbal supplements or thiazide diuretics~* No other concurrent investigational or commercial agents or therapies

- Gender: MALE
- Minimum Age: 18 Years
- Maximum Age: 120 Years
- Healthy Volunteers: f

Study Arms:
- licorice root extract and docetaxel (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Prospective Study of TW in Treatment of IgAN With Asymptomatic Abnormal Urinalysis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~1. 18-60 years old but no requirement for gender~2. All well fit the Diagnostic Criteria for Primary IgAN and IgAN with asymptomatic abnormal urinalysis~3. Informed consent is obtained from each research subject who agrees to conduct a periodic follow-up according to the research arrangement~Exclusion Criteria:~1. Secondary IgA nephropathy, such as Henoch-Schönlein purpura nephritis, Lupus nephritis and so on~2. Some secondary kidney diseases like diabetic nephropathy or other systemic diseases which may effect the pathologic and physiological function of kidney like hypertension and arteriosclerosis~3. Severe infection~4. Abnormality of liver function with glutamic pyruvic transaminase (GPT) or glutamic-oxal(o)acetic transaminase (GOT) more than twice upper limit of normal~5. Women during pregnancy and lactation~6. Patients need to procreation lately~7. Patients treated with TW or ARB within 4 months

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 60 Years
- Healthy Volunteers: f

Study Arms:
- immunosuppressor (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Radiation Therapy Followed by Bleomycin in Treating Adult Patients With Newly Diagnosed Supratentorial Glioblastoma Multiforme

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
DISEASE CHARACTERISTICS:~* Histologically confirmed supratentorial glioblastoma multiforme (with areas of necrosis) by surgical biopsy or excision within 4 weeks of study~* Tumor and/or any associated edema limited to one hemisphere and unifocal~* No gross invasion of a ventricular surface~* Tumor accessible~* No other astrocytoma~* No multifocal or recurrent malignant glioma~* No disease below the tentorium or beyond the cranial vault~PATIENT CHARACTERISTICS:~Age:~* Adult~Performance status:~* Zubrod 0-1~Life expectancy:~* At least 8 weeks~Hematopoietic:~* Hemoglobin at least 10 g/dL (transfusion allowed)~* Absolute neutrophil count at least 1,500/mm\^3~* Platelet count at least 100,000/mm\^3~Hepatic:~* Bilirubin no greater than 2.0 mg/dL~* Serum glutamic-oxaloacetic transaminase (SGOT) or Serum glutamic-pyruvic transaminase (SGPT) no greater than 2 times normal~Renal:~* Blood Urea Nitrogen (BUN) no greater than 25 mg/dL~* Creatinine no greater than 1.5 mg/dL~Other:~* Not pregnant or nursing~* Fertile patients must use effective contraception~* No hypersensitive or idiosyncratic reaction to bleomycin~* No other prior malignancies within the past 2 years except nonmelanomatous skin cancer or carcinoma in situ of the cervix or urinary bladder~* No other major medical illness or psychiatric impairment that would preclude study participation~PRIOR CONCURRENT THERAPY:~Biologic therapy:~* Not specified~Chemotherapy:~* No prior chemotherapy for glioblastoma multiforme~* No prior radiosensitizer for glioblastoma multiforme~Endocrine therapy:~* Not specified~Radiotherapy:~* No prior radiotherapy to the head or neck resulting in overlapping radiotherapy fields~Surgery:~* See Disease Characteristics~* Recovered from prior surgery

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Radiation therapy followed by bleomycin via Ommaya reservoir (Type: EXPERIMENTAL): 60.0 Gy/30 fractions x 2.0 Gy. Then within 2-6 weeks after completion of radiation therapy or at the time a patient experiences disease progression during or immediately after completion of radiation therapy, if clinically feasible, a modified Ommaya reservoir is implanted with the delivery catheter in the tumor or tumor cyst/cavity. Bleomycin, 15 units per week, is then given via the Ommaya reservoir without interruption for a maximum of two years as long as there is no toxicity above grade 3 or evidence of disease progression.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Masimo Radical-7 Monitor a Useful Adjuvant During Major Spine Surgery

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: None
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Patients scheduled to undergo multiple level spine surgery procedures~* 18 - 80 years of age~* American Society of Anesthesiologists (ASA) Class I - III adults of either sex~* Pregnant women~Exclusion Criteria:~* Patients with a perfusion index less than 1 or low confidence reading~* Patients with nail polish and /or a nail deformity on a finger that would used for sensor placement~* Patient undergoing cardio-pulmonary bypass

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: feasibility